Catalent Announces Two Appointments to Executive Leadership Team in Management Realignment
Somerset, N.J. (PRWEB) September 16, 2016 -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Alessandro Maselli is to become its new Senior Vice President of Global Operations, while Christine Dolan will assume the role of Senior Vice President of Global Product Development.
Mr. Maselli has extensive operations experience at several global organizations, and previously acted as Vice President of Operations for Catalent’s Drug Delivery Solutions business in Europe. Prior to this, he was General Manager of Catalent’s Zydis® orally disintegrating tablet facility in Swindon, UK, and held a number of other senior management and operational roles, having joined the organization from Alstom in 2010. Before joining Alstom, Mr. Maselli had worked in business management and operations positions for SGS and ABB respectively.
He holds a master’s and bachelor’s degree in engineering from Università degli Studi di Roma 'La Sapienza,' Rome.
Mr. Steve Leonard, who previously held the position, has decided to leave the company in early 2017, but will continue in an advisory position until that time, in order to assist with the transition.
Ms. Dolan was appointed Vice President, Global Softgel Operations in November 2013, with responsibility for Catalent’s 11 Softgel manufacturing and development sites, spanning five continents. In this role, she had operational responsibility for more than 3,500 employees.
She began her career with Catalent in 2009 in Global Quality, and in 2010 was named General Manager for Catalent’s Woodstock, Illinois, sterile technologies facility. She had previously acted as Vice President of Operations for the Development and Clinical Services Business Unit, with operational responsibilities for five of Catalent’s facilities providing clinical manufacturing, packaging, and analytical development of both large and small molecules. Following Catalent’s acquisition of Aptuit’s clinical trials business in 2011, Ms. Dolan was named Vice President and General Manager of Development and Analytical Solutions, which included operations in Kansas City, Missouri, Morrisville, North Carolina, and Swindon, U.K. Prior to Catalent, she worked as a microbiologist for Smith & Nephew Solopak, and also Amersham Health and GE Healthcare, where she served in various leadership roles.
Ms. Dolan holds a bachelor’s degree in biology from Lenoir-Rhyne College, North Carolina.
“We are confident that both Alessandro and Christine will continue to drive the organization forward and believe that this management realignment will bring value, not only to Catalent as a business, but to our customers, and ultimately patients,” commented John Chiminski, Catalent’s President and CEO. He added, “At the same time, it is important to recognize the enormous impact that Steve has made on the company’s transformation and growth since his appointment in 2009. We wish him all the best for the future and will always be appreciative of his professionalism, strategic contribution, energy and insight.”
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,200 people, including over 1,400 scientists, at more than 30 facilities across 5 continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
Chris Halling, Catalent Pharma Solutions, http://www.catalent.com, +44 7580041073, [email protected]
Share this article